Rezultati pretraživanja
  1. First Cork patient enrolled onto the DICE trial : phase 2 study of with in advanced with bone metastasis. Ask your oncologist about potential suitable trials recruiting in Ireland

  2. 8. velj 2018.

    Maha Hussain shows activity in non metastatic CRPC.

  3. Article Online: Optimal of and acetate plus in metastatic castration-resistant : a randomised, open-label, phase 2 crossover trial

    Prikaži ovu nit
  4. 18. pro 2019.
  5. 31. svi 2019.

    Dr. Kim Chi phase II of cabazitaxel (CAB) vs or in poor-risk showed improved CBR with CAB and prolonged SD, trend to OS benefit with first-line CAB

  6. 7. lis 2017.
  7. 31. svi 2019.

    Dr. Morris: simply not that much more anticancer activity w/addition of to vs enza alone in phase III trial in . More AEs with combination

  8. 16. velj 2017.

    Dr.Antonarakis:full length Androgen receptor neg CTCs may predict response to &

  9. 4. lip 2017.

    In head to head comparison w better PSA resp cw but no difference in PFS in

  10. 14. ožu 2018.

    .Kayla Gu, MS1 speaks to the Board of Regents on the behalf of urging to drop the patent claim in India on / that would bar affordable access to a lifesaving prostate cancer drug

  11. 13. srp 2018.
  12. 14. velj 2019.

    Karim Fizazi presents data on in M0 CRPC - with MFS benefit similar to and . Low fatigue. Now there are 3 drugs. Will the blood brain barrier be the great separator?

  13. 6. lip 2018.

    Our recent ASCO abstract describing the ENZADA trial for patients with newly diagnosed metastatic prostate cancer. This trial is only available at and is testing the combination of ADT + docetaxel + .

  14. 7. velj 2018.

    Outstanding results of Enzalutamide in M0 castration resistant prostate cancer!

  15. 14. velj 2019.

    Genomic drivers of poor prognosis and enzalutamide resistance in mCRPC, William S. Chen of . RB1 loss and Wnt/CTNNB1 associated with shorter survival and Wnt/beta-catenin pathway is a predictive of resistance.

    Ovo je potencijalno osjetljiv multimedijski sadržaj. Saznajte više
  16. 14. srp 2018.

    Fascinating work on interaction between gut mileu and androgen axis-targeted therapies ( ) -- bidirectional relationship with implications on PCa response to

  17. 2. lip 2019.

    trial: in hormone sensitive metastasic : benefit in overall survival, although this benefitnis not observed in patients treated with docetaxel. More follow-up is needed.

  18. 3. lip 2017.

    Dorff - 42% of ARV7+ patients treated with had response

  19. 8. velj 2018.

    high-risk non-metastatic castrate-refractory : PROSPER vs SPARTAN ( vs ) - you decide!

  20. BREAKING NEWS! FDA approves (Xtandi) for the treatment of non-metastatic castration-resistant (non-metastatic CRPC). PCF funded the early research to synthesize this drug. Read more:

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.